Lowest Price Guaranteed
Slides
237
Last Updated
January 2025
View Count
10051
The global whole genome sequencing market size is estimated at USD 2.63 billion in 2025 and is poised to reach USD 13.62 billion by 2035; expected to grow at a CAGR of 17.9%.
 |
To learn more about this report, request a free sample copy
Whole genome sequencing (WGS) is a comprehensive process for analyzing complete genomic information by using sequencing technologies. With rapid technological advancements such as CRISPR-Cas genome editing and next generation sequencing technology, scientist are able to identify mutations, alterations and variations that cause genetic disorders. Whole genome sequencings hold immense potential in medical applications including disease detection, drug development and characterization of biomarkers. With growing concern of chronic diseases and cancer worldwide, pharmaceutical companies are focusing on utilizing genomic research to develop precision medicines for targeting diseases. In such instances, whole genome sequencing emerged as an uncompromised solution that helps to identify small and large variants, gene expression and disease mechanism with higher accuracy and resolution.
Further, whole genome sequencing is also gaining traction in cancer research to understand the role of inherited genes in cancer and designing the treatment plan. Considering the key benefits of whole genome sequencing in disease diagnosis and treatment planning, the key industrial players, such as Illumina, Pfizer and Thermo Fisher Scientific are accelerating their technological innovations to make sequencing accessible and affordable. The companies are also actively participating at global events in order to showcase their portfolio. In November 2024, Illumina presented several updates on innovations in proteomics, whole genome sequencing and single-cell technologies in the American Society of Human Genetics Annual Meeting) held in Denver.
Along with innovations, several partnerships and collaborations have been done by the stakeholders for product portfolio enhancements. For instance, in February 2024, Complete Genomics and seqWell signed a partnership in order to expand a range of library preparation product that will be available for the purpose of complete Genomics. Under this agreement, both company’s joint forces to ensure that genome library products developed by seqWell are compatible with next generation sequencing and automation portfolios of Complete Genomics. Driven by the growing initiatives and partnerships, we believe that whole genome sequencing market will expand steadily during the forecast period.
The research report provides invaluable information about industrial players who are presently active across various segments of the industry as mentioned in the table below.
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | Till 2035 | |
| Market Size 2035 | $13.62 Billion | |
| CAGR (Till 2035) | 17.9% | |
| Type of Product |
|
|
| Type of Sequencing |
|
|
| Type of Workflow |
|
|
| Type of Application |
|
|
| End Users |
|
|
| Geographical Regions |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
Available | |
One of the key objectives of the whole genome sequencing market report was to estimate the current size, opportunity and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.
The market analysis also features the likely distribution of the current and forecasted opportunity within the market distributed across various segments, such as type of product (instruments, consumables and services), type (large whole genome sequencing and small whole genome sequencing), type of workflow (pre-sequencing, sequencing and data analysis), type of application (human whole genome sequencing, plant whole genome sequencing, animal whole genome sequencing and microbial whole genome sequencing), by end-user (academic & research institutes, hospitals & clinics, pharmaceutical & biotechnology companies and other end users) and geographical region (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America) and leading players.
In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. The financial figures mentioned in this market report are in USD, unless otherwise specified.
Based on the type of product, the global whole genome sequencing market is segmented into instruments, consumables and services. According to the market study, currently consumables segment holds the dominating position in the market, with a share of 66%. This can be attributed to the growing demand for consumable products, such as kits and reagents for genome sequence, sample preparation, and library preparation. However, it is important to highlight here that services segment will show lucrative growth potential and is expected to grow at a higher CAGR during the forecast period. This can be attributed to the fact that whole genome sequencing has become an integral part of genome research and drug development. Thus, growing dependency on genomic studies has significantly increased the demand for whole genome sequencing technologies for data interpretation.
As whole genome sequencing continues to gain traction, the need for specialized sequencing services will increase, which is anticipated to be a key growth factor for this segment. Furthermore, the rising shift towards outsourcing for sequencing projects for cost reduction is likely to be a key growth factor of this segment. In July 2024, Labcorp expanded its collaboration with Ultima Genomics, in order to explore WGS clinical applications, based on UG 100™ sequencing solution and ppmSeq™ technology. As stated by Shakti Ramkissoon (Vice President, Medical Lead for Oncology, Labcorp), “By combining Labcorp's leadership, testing capabilities and expansive network with the accuracy, scalability and cost-effectiveness of Ultima's technology, we can help transform oncology testing for pathologists, oncologists and our biopharmaceutical partners. Through this collaboration, Labcorp aims to drive increased efficiency, scalability and cost-effectiveness while improving access to affordable genetic testing in emerging areas with significant unmet need.”
This segment highlights the distribution of global whole genome sequencing market into large whole genome sequencing and small whole genome sequencing. Among these, large whole genome sequencing occupies the highest share (77%) of the market driven by the increasing focus on genomic research to study genetic variations and their correlation with genetic diseases. In addition, the study of human genomes of large populations enables the researchers to design personalized therapeutics that aid in treating wide range of genetic diseases.
However, in the long run, small whole genome sequencing is likely to grow at a substantial CAGR during the forecast period. This can be attributed to the fact that small whole genome sequencing technology allows accurate sequencing of smaller genomes in bacteria and viruses. The information about small genomes in microorganisms helps in understanding antibiotic resistances and infectious diseases. Additionally, the trend of single-cell omics to treat diseases at molecular level has further supported the growth of this segment during the forecast period.
The global whole genome sequencing market size is further categorized based on type of workflow into pre-sequencing, sequencing and data analysis. According to our market study, currently sequencing segment accounts for the highest share (nearly 55%) of the market. This is primarily due to the ability of whole genome sequencing technologies in sequencing entire genome with higher accuracy, making it a potential solution for understanding diseases and clinical applications. Additionally, the high demand for user-friendly sequencing workflow for widespread adoption across different industrial verticals has further bolstered the growth of this segment. However, in the long run, data analysis segment is likely to grow at a higher CAGR during the forecast period driven by the demand for sophisticated data analysis solutions for interpreting data generated during genome sequencing.
The global market is distributed across different type of applications, such as human whole genome sequencing, plant whole genome sequencing, animal whole genome sequencing and microbial whole genome sequencing. Currently, human whole genome sequencing occupies the highest whole genome sequencing market share (nearly 65%), driven by extensive research on genomics for the development of personalized medicine. Furthermore, whole genome sequencing plays a significant role in understanding genetic diseases and cancer genomics. The information about human genomics helps in the development of targeted therapies to treat diseases. Additionally, increasing research on human genomics has further propel the demand for whole genome sequencing in human applications. Driven by the ongoing demand, this segment will continue to grow at a higher CAGR during the forecast period.
This segment highlights the distribution of global whole genome sequencing market across different end users, such as academic & research institutes, hospitals & clinics, pharmaceutical & biotechnology companies and other end users. Among these end users, the academic & research institutes account for the highest share (nearly 50%) of the market. This is likely to be the result of increasing adoption of whole genome sequencing technologies by academic & research institutes for drug research and genomic studies.
However, in the long run, hospitals & clinics segment is likely to grow at a higher CAGR during the forecast period. This substantial growth can be attributed to the fact that healthcare experts are increasing using whole genome sequencing and next generation sequencing technologies for disease diagnosis and personalized treatment plans. Whole genome sequencing offers comprehensive details about genome alteration and sequences that are enrolled in the diseases, making it a valuable tool for designing treatment.
The global whole genome sequencing market is distributed across different geographical regions, such as North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. Currently, North America occupies the highest share (nearly 55%) of the market. This is likely to be the result of growing research on human genomics to understand disease at genomic level and rising government initiatives to address the growing concern of genetic diseases in this region.
However, in the long run, the market for whole genome sequencing in Asia-Pacific is likely to grow at a substantial CAGR during the forecast period. This unprecedented growth is due to the increasing spending on genomic research and rising awareness about genetic mutations and diseases due to genome alteration. For instance, Indian state government has initiated a grant of INR 10 Lakh to INR 2 Crore to Kerala Genome Data Center for genome sequencing and data generation project. The project fund can be utilized to initiate research across microbial genomics, sickle cell anemia, and other chronic diseases that result in higher mortality rate.
The “Whole Genome Sequencing Market Report: Industry Trends and Global Forecast, till 2035” the market report features a detailed study of the current market landscape, market size, market forecast and future opportunities for the DNA-based vaccine developers. Further, the market research report underlines an in-depth analysis, highlighting the capabilities of stakeholders engaged in the market.
Currently, the market landscape seems competitive, featuring the presence of several well-established new-entrants who are currently engaged in the industry. In order to enhance the global reach, several industrial players are taking strategic initiatives including collaborations and partnerships. For instance, in October 2024, Illumina and National Taiwan University (NTU) Hospital signed a Memorandum of Understanding (MoU) for beginning a “Whole Genome Sequencing” project. Similarly, several other industrial players are increasing the research efforts to meticulously develop whole genome sequencing technologies that aid in early disease diagnosis and treatment planning. Overall, the market seems well-fragmented witnessing the presence of small, mid-sized and large companies who are currently aiming to strengthen their market positions by expanding the product portfolio.
Some of the key drivers that are propelling market growth includes growing incidence of cancer and heightened demand for oncology precision medicine. Notably, with rising cases of inherited cancers or mutations, researchers are focusing on understanding cancer genomics to design targeted therapies for treating cancer patients. Whole genome sequencing technology and genome editing technologies (such as CRISPR-Cas gene technology) enabled researchers to understand the disease at genomic level, anticipated to be a key factor for widespread adoption of whole genome sequencing.
Moreover, expanding usage of whole genome sequencing in precision medicine is a key growth factor for the market. This can be attributed to the fact that whole genome sequencing plays a significant role in understanding genome profile, gene alteration and mutation. This information helps in developing personalized medicine to target disease at genetic level. Furthermore, with increasing usage of whole genome sequencing in diagnosis genetic disorders, understanding pharmacogenomics and prenatal screening has further fueled the market growth during the forecast period.
Despite increasing demand for whole genome sequencing, the market is witnessing several challenges that limits its adoption. Some of the potential challenges include high installation cost, accessibility / scalability challenges and data storage issues. Notably, the high upfront cost associated with installation and integration of whole genome sequencing with existing systems may seem as a significant barrier for the industrial players specifically from low to middle income countries. Moreover, whole genome sequencing technologies and solutions require maintenance on regular basis and skilled personnels for operation which further enhanced its overall cost. It is important to highlight here that limited awareness about whole genome sequences may create challenges in increasing their accessibility globally. In addition to cost, whole genome sequencing involves data transmission to different healthcare systems for further analysis which raises concern of data privacy.
Some of the top whole genome sequencing market growth factors are technological advancements and integration of artificial intelligence. It is important to highlight here that currently, the market players are greatly emphasizing the development of next generation sequencing platforms with high accuracy, higher throughput and faster turn-around times. Moreover, industrial players are aiming to reduce the cost of sequencing whole genome to make it accessible across the globe for clinical applications. Moreover, the current aim of market players is on integrating machine learning and artificial intelligence with whole genome sequencing technologies to enhance the sequencing capabilities and automating the analysis process. With the integration of AI algorithm, researchers can quickly process large amounts of datasets with higher precision. The capabilities of quick analysis can improve genome understanding, making it a valuable application for personalized medicine.
The global whole genome sequencing market is currently valued at USD 2.63 billion and is anticipated reach at USD 13.62 billion by 2035; expected to grow at a CAGR of 17.9%. Notably, the market is primarily driven by the rising partnerships for the development of innovative whole genome sequencing solutions. For instance, in March 2024, Fabric Genomics announced a strategic partnership with Intermountain Children’s Health in order to enhance precision diagnosis of both children and infants using whole genome sequencing from Broad clinical labs. As stated by Dr. Martin Tristani-Firouzi (Pediatric Oncologist, University of Utah Health and Intermountain Primary Children’s Hospital),” This partnership allows us to quickly and cost-effectively access top-tier clinical-grade genome sequencing and reporting, more accurate diagnoses for these infants, and the ability to reanalyze the data, all of which ultimately will improve outcomes and enhance the quality of care we deliver to children. It also allows us to integrate with our research organization in the Department of Pediatrics at the University of Utah and continuously develop research protocols for unsolved cases.
Driven by the ongoing partnerships, we believe that the market will continue to expand at a steady pace during the forecast period. This report covers the market trends in each of the key geographies.
Examples of key players engaged in this domain (which have also been captured in this report) include Agilent Technologies, Azenta (GENEWIZ), BGI, Illumina, Oxford Nanopore Technologies, ProPhase Labs (Nebula Genomics), Pacific Biosciences, Psomagen, QIAGEN and Thermo Fisher Scientific. This market report includes an easily searchable excel database of all the companies focusing on the development of whole genome sequencing solutions
Several recent developments have taken place in the whole genome sequencing industry. We have outlined some of these recent initiatives below.